Takeshima, Hiroshi

Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor

Takeshima, H., Nishimura, S., Matsumoto, T., Ishida, H., Kangawa, K., Minamino, N., Matsuo, H., Ueda, M., Hanaoka, M., Hirose, T., et al. (1989) · Nature

Ion channel regulation and functionCardiac electrophysiology and arrhythmias

Cited by 1,146

Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors

Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., Walwyn, W., Kieffer, B. L., Takeshima, H., Carroll, F. I., Maidment, N. T., et al. (2003) · The Journal of Neuroscience

Neuropeptides and Animal PhysiologyPain Mechanisms and Treatments

Cited by 211

Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons

Pigoni, M., Wanngren, J., Kuhn, P.-H., Munro, K. M., Gunnersen, J. M., Takeshima, H., Feederle, R., Voytyuk, I., De Strooper, B., Levasseur, M. D., et al. (2016) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsProtease and Inhibitor Mechanisms

Cited by 125

Parkinson’s disease-associated ATP13A2/PARK9 functions as a lysosomal H+,K+-ATPase

Fujii, T., Nagamori, S., Wiriyasermkul, P., Zheng, S., Yago, A., Shimizu, T., Tabuchi, Y., Okumura, T., Fujii, T., Takeshima, H., et al. (2023) · Nature Communications

Parkinson's Disease Mechanisms and TreatmentsAutophagy in Disease and Therapy

Cited by 72